Search results for " Prediabetic State"

showing 4 items of 4 documents

Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

2014

ObjectiveDiabetes mellitus (DM) is one of the most frequent complications of Cushing's syndrome (CS). The aim of this study was to define the changes in insulin sensitivity and/or secretion in relation to glucose tolerance categories in newly diagnosed CS patients.DesignCross-sectional study on 140 patients with CS.MethodsA total of 113 women (80 with pituitary disease and 33 with adrenal disease, aged 41.7±15.7 years) and 27 men (19 with pituitary disease and eight with adrenal disease, aged 38.1±20.01 years) at diagnosis were divided according to glucose tolerance into normal glucose tolerance (CS/NGT), impaired fasting glucose and/or impaired glucose tolerance (CS/prediabetes), and diabe…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatmentCushing's syndromeSettore MED/13 - EndocrinologiaPrediabetic StateImpaired glucose toleranceEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionGlucose IntoleranceDiabetes MellitusmedicineHumansInsulinPrediabetesCushing SyndromeRetrospective StudiesCushing DiabetesGlucose tolerance testhypercortisolismmedicine.diagnostic_testbusiness.industryInsulinGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseImpaired fasting glucoseDiabetes and MetabolismCross-Sectional StudiesPhenotypeEndocrinologyDiabetes Mellitus Type 2diabeteFemaleInsulin ResistanceMetabolic syndromebusinessAdult; Cross-Sectional Studies; Cushing Syndrome; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydrocortisone; Insulin; Insulin Resistance; Male; Middle Aged; Phenotype; Prediabetic State; Retrospective Studies; Endocrinology Diabetes and Metabolism; EndocrinologyType 2European Journal of Endocrinology
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Risk of progression to diabetes and mortality in older people with prediabetes: The English longitudinal study on ageing

2022

Abstract Aims Prediabetes is used to identify people at increased risk for diabetes. However, the importance of prediabetes in older populations is still poorly explored. Therefore, we aimed to investigate the prevalence of prediabetes, based on either glycated haemoglobin (HbA1c) levels or fasting glucose (FG) levels, or both and the progression of prediabetes to diabetes or to mortality in older participants of the English Longitudinal Study on Ageing. Materials and methods Prediabetes was categorized based on HbA1c levels (5.7%–6.4%) and/or FG levels (5.6–7.0 mmol/L). Information regarding mortality and incident diabetes were recorded during follow-up period of 10 years. Results In 2027 …

Glycated HemoglobinBlood GlucoseMaleAgingGlycated Hemoglobin AdiabetesEnglish Longitudinal Study on Ageing (ELSA)prediabetesGeneral MedicineEnglish Longitudinal Study on Ageing (ELSA); diabetes; older people; prediabetes; Aged; Aging; Blood Glucose; Female; Glycated Hemoglobin A; Humans; Longitudinal Studies; Male; Risk Factors; Prediabetic Stateprediabetes diabetes older people English Longitudinal Study on Ageing (ELSA)older peoplePrediabetic StateRisk FactorsHumansFemaleLongitudinal StudiesGeriatrics and GerontologyResearch PaperAgedAge and Ageing
researchProduct

Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

2021

Background and aims: Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. Methods and results: In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We…

MaleTime FactorsEndocrinology Diabetes and MetabolismCardiovascular risk Direct acting antiviralsHepatitis C virusPrediabetes Aged Antiviral Agents Cardiovascular Diseases FemaleHeart Disease Risk Factors Hepatitis C Humans Incidence Italy Longitudinal Studies Male Middle Aged Prediabetic State Prospective Studies Protective Factors Retrospective Studies Risk AssessmentTime Factors Treatment Outcome Viral LoadMedicine (miscellaneous)Type 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeDIRECT ACTING ANTIVIRALSLiver disease0302 clinical medicineLongitudinal StudiesProspective StudiesPrediabeteseducation.field_of_studyNutrition and DieteticsIncidenceMiddle AgedViral LoadHepatitis CTreatment OutcomeItalyCardiovascular DiseasesCohortFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyHepatitis C virusPopulation030209 endocrinology & metabolismAntiviral AgentsRisk AssessmentPrediabetic State03 medical and health sciencesInternal medicinemedicineHumanseducationAgedRetrospective Studiesbusiness.industryProtective FactorsCardiovascular riskmedicine.diseaseHeart Disease Risk FactorsDirect acting antiviralHepatitis C virubusinessPrediabetesMace
researchProduct